Assistant Professor, Department of Aerospace and Mechanical Engineering, and Assistant Professor (Concurrent), Chemical and Biomolecular Engineering, College of Engineering
Office: 141 Multidisciplinary Research Building
Our laboratory works at the interface of engineering and medicine, with a motivation on making stem cell and molecular therapies as an effective method to model and treat diseases. Toward these goals, we integrate our core expertise in stem cell engineering, biomaterials synthesis, and micro/nano- technologies for their application in regenerative medicine, disease modeling, and drug delivery.
- Stem Cell Engineering. Stem cells have the potential to induce repair and participate in regenerating injured tissues. However, during the course of chronic diseases (e.g., cardiovascular diseases and diabetes) and aging, resident and circulating stem cells are subject to stress-induced premature dysfunction that limits their therapeutic use. Our lab is interested to utilize engineering approaches to understand the mechanisms governing stem cell fate and to control stem cell differentiation, in particular for their therapeutic application in cardiovascular and lymphatic disorders.
- Biomaterials for Stem Cell Morphogenesis. Promoting blood and lymphatic vasculature is important for tissue engineering and can be used as therapeutic interventions to treat ischemia and lymphedema. We are studying the role of growth factors and extracellular matrices (ECMs) in blood and lymphatic formation. Our lab utilizes bio-mimetic materials with spatial and temporal control for stem cells to undergo morphogenesis into vascular and lymphatic vasculatures. We are applying this approach toward therapeutic interventions to treat ischemia, lymphedema, and wound healing in animal models.
- Targeted Drug Delivery. Many available drugs are effective at a very small therapeutic window without causing systemic side effects. For example, anti-coagulant drugs are effective at preventing blood clots, but can also cause systemic bleeding. To overcome these limitations, we are interested in harnessing the ability of stem cell and antibody for site-specific delivery of therapeutics.
Would you like to support Prof. Hanjaya-Putra's research?
- Donny Hanjaya-Putra, Carolyn Haller, Xiaowei Wang, Erbin Dai, Bock Lim, Liyung Liu, Patrick Jaminet, Joy Yao, Amy Searle, Thomas Bonnard, Christoph E. Hagemeyer, Karlheinz Peter, Elliot L. Chaikof, "Platelet-Targeted Dual Pathway Antithrombotic Inhibits Thrombosis with Preserved Hemostasis," JCI Insight, 2018 Aug 9; 3(15)
- Sravanti Kusuma, Yu-I Shen, Donny Hanjaya-Putra, Prashant Mali, Linzhao Cheng, Sharon Gerecht, “Self-Organized Vascular Networks from Human Pluripotent Stem Cells in a Synthetic Matrix,” Proc Natl Acad Sci U S A, 2013 Jul 30; 110(31): 12601-6
- Donny Hanjaya-Putra, Yu-I Shen, Abby Wilson, Sudhir Khetan, Karen Fox-Talbot, Charles Steenbergen, Jason A. Burdick, Sharon Gerecht, “Integration and Regression of Implanted Human Vascular Networks during Deep Wound Healing,” Stem Cell Translational Medicine, 2013 Apr; 2(4):297-306
- Donny Hanjaya-Putra, Kyle T. Wong, Kelsey Hirotsu, Sudhir Khetan, Jason A. Burdick, Sharon Gerecht, “Spatial Control of Cell-Mediated Degradation to Regulate Vasculogenesis and Angiogenesis in Hyaluronan Hydrogels,” Biomaterials, 2012, Sep; 33(26):6123-31
- Donny Hanjaya-Putra, Vivek Bose, Yu-I Shen, Jane Yee, Sudhir Khetan, Karen Fox-Talbot, Charles Steenbergen, Jason A. Burdick, Sharon Gerecht, “Controlled Activation of Morphogenesis to Generate a Functional Human Microvasculature in a Synthetic Matrix,” Blood, 2011, Jul 21; 118(3):804-15
- Donny Hanjaya-Putra, Jane Yee, Doug Ceci, Rachel Truitt, Derek Yee, Sharon Gerecht, “Vascular Endothelial Growth Factor and Substrate Mechanics Regulate in vitro Tubulogenesis of Endothelial Progenitor Cells.” Journal of Cellular and Molecular Medicine, 2010 Oct; 14(10):2436-47